{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:38:48Z","timestamp":1793993928107,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T00:00:00Z","timestamp":1633219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.eclinm.2021.101163","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T19:51:28Z","timestamp":1635277888000},"page":"101163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials"],"prefix":"10.1016","volume":"41","author":[{"given":"Natalie","family":"Staplin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4184-2541","authenticated-orcid":false,"given":"Alistair J.","family":"Roddick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Emberson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Reith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Riding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Wonnacott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apexa","family":"Kuverji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Herrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2021.101163_bib0001","series-title":"Guidance for Industry on Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. A Notice by the Food and Drug Administration on 12\/19\/2008","year":"2021"},{"issue":"22","key":"10.1016\/j.eclinm.2021.101163_bib0002","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eclinm.2021.101163_bib0003","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2021.101163_bib0004","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.eclinm.2021.101163_bib0005","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2021.101163_bib0006","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.eclinm.2021.101163_bib0007","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2021.101163_bib0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.eclinm.2021.101163_bib0009","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.eclinm.2021.101163_bib0010","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.eclinm.2021.101163_bib0011","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2021.101163_bib0012","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.eclinm.2021.101163_bib0013","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2021.101163_bib0014","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eclinm.2021.101163_bib0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.eclinm.2021.101163_bib0016","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/oby.20663","article-title":"Canagliflozin: effects in overweight and obese subjects without diabetes mellitus","volume":"22","author":"Bays","year":"2014","journal-title":"Obesity (Silver Spring)"},{"issue":"24","key":"10.1016\/j.eclinm.2021.101163_bib0017","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2021.101163_bib0018","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.eclinm.2021.101163_bib0019","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.eclinm.2021.101163_bib0020","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2337\/dc17-1551","article-title":"Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eclinm.2021.101163_bib0021","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.eclinm.2021.101163_bib0022","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.eclinm.2021.101163_bib0023","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ajkd.2020.06.018","article-title":"Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program","volume":"77","author":"Neuen","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"13","key":"10.1016\/j.eclinm.2021.101163_bib0024","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurheartj\/ehab094","article-title":"Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial","volume":"42","author":"Heerspink","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.eclinm.2021.101163_bib0025","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.eclinm.2021.101163_bib0026","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2112411","article-title":"Empagliflozin and Major Renal Outcomes in Heart Failure","author":"Packer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2021.101163_bib0027","volume":"Volume 1","year":"1990"},{"key":"10.1016\/j.eclinm.2021.101163_bib0028","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020)","article-title":"Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses","author":"Deeks","year":"2020"},{"issue":"10","key":"10.1016\/j.eclinm.2021.101163_bib0029","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1681\/ASN.2019121312","article-title":"Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program","volume":"31","author":"Oshima","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.eclinm.2021.101163_bib0030","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10254","key":"10.1016\/j.eclinm.2021.101163_bib0031","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.eclinm.2021.101163_bib0032","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eclinm.2021.101163_bib0033","series-title":"Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. (DELIVER)","year":"2020"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021004430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021004430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:10:24Z","timestamp":1762888224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537021004430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":33,"alternative-id":["S2589537021004430"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.101163","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.101163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101163"}}